Cytokinetics, Incorporated is an advanced biopharmaceutical company dedicated to the research, development, and commercialization of therapies that modulate muscle function. These novel compounds aim to address debilitating diseases. The core of their pipeline consists of small molecule drug candidates specifically designed to influence muscle performance and contraction at a fundamental level. Currently, several key programs are in late-stage clinical trials: Omecamtiv mecarbil, a cardiac myosin activator, is being evaluated in Phase III for heart failure patients. Reldesemtiv, which targets skeletal muscle troponin activation, is in Phase III development for amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). Aficamten, a cardiac myosin inhibitor, has reached Phase III for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Earlier-stage assets include CK-136, a cardiac troponin activator, and CK-3772271, another cardiac myosin inhibitor, both currently undergoing Phase I clinical assessment. The company also maintains a strategic collaboration with Astellas Pharma Inc. Established in 1997, Cytokinetics is headquartered in South San Francisco, California.

Employees - 498, CEO - Robert I. Blum, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -2.64, Piotroski Score(max is 10): 3, Working Capital: $640280000, Total Assets: $1273478000, Retained Earnings: $-3692750000, EBIT: -745688000, Total Liabilities: $2100046000, Revenue: $105815000

- Current Price $ - Analyst Target Price $